Skip to Main Content

The Food and Drug Administration has agreed to review a treatment for a rare, genetically defined form of ALS developed by Biogen, even though results from a clinical trial failed to show a definitive benefit for patients.

Biogen said Tuesday that U.S. regulators accepted its application for the drug, called tofersen, and that it will undergo a priority review with an approval decision expected by Jan. 25.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment